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Low-molecular-weight heparin prevents high glucose- and phor- Among several growth hormones and cytokines sug-
bol ester-induced TGF-1 gene activation. gested to be involved in the pathogenesis of diabetic
Background. Hyperglycemia-induced overexpression of pro- nephropathy, prosclerotic cytokine transforming growth
sclerotic transforming growth factor-1 (TGF-1) has been
factor- (TGF-1) has been implicated as a key mediatorimplicated in the pathogenesis of diabetic nephropathy. Since
leading to basement membrane thickening, mesangialprevious in vivo studies demonstrated a renoprotective effect
of low-molecular-weight (LMW) heparin in experimental ani- matrix expansion, and glomerulosclerosis [1–10]. Results
mals, and recent in vitro data showed an interaction of this drug from numerous studies, including data from our own
with the overactivated TGF-1 cascade in high glucose- and laboratory, indicate that in experimental and human dia-
phorbol ester-stimulated mesangial cells, we studied the molec-
betes [5, 6, 9] as well as in vitro, high glucose concentra-ular mechanism of these effects on TGF-1 gene expression.
tions lead to an increase in TGF-1 mRNA levels inMethods. Mesangial cells were stimulated with 30 mmol/L
glucose or with 0.5 mol/L phorbol ester [phorbol myristate ace- kidney and in cultured mesangial cells [6–8, 10, 11]. Fur-
tate (PMA)] in the absence or presence of LMW heparin. TGF-1 thermore, activation of protein kinase C (PKC) has been
promoter activity was determined in promoter-reporter lucifer- linked to the development of late diabetic complications
ase assays. The effect of LMW heparin on the binding of nu-
including diabetic nephropathy [3, 6, 12–14], and phorbolclear proteins to a regulatory activator protein-1 (AP-1) site,
esters [phorbol myristate acetate (PMA)], as PKC activa-which mediates the high glucose and PMA responsiveness of
tors were shown to increase TGF-1 mRNA levels inthe TGF-1 promoter, was studied by electrophoretic mobility
shift assays. mesangial cells [15]. Therefore, prevention of the up-
Results. The presence of LMW heparin completely prevented regulation of TGF-1 in diabetic patients is suggested
TGF-1 gene activation in both high glucose- and PMA-stimu- to ameliorate the pathobiochemical alterations of thelated cells. Preincubation of the cells with LMW heparin and
kidney [16, 17]. Previous studies demonstrate that treat-subsequent stimulation of the cells with both stimuli yielded
ment with the glycosaminoglycan (GAG) low-molecu-the same result. Furthermore, treatment with LMW heparin
prevented the enhanced binding of nuclear proteins to the lar-weight (LMW) heparin inhibits alterations of the glo-
regulatory AP-1 site, while binding to a Sp1 site was unaffected. merular basement membrane and the mesangial matrix
Basal promoter activity and basal AP-1 binding also was re- in the diabetic streptozotocin animal model [18–20],
duced by LMW heparin. The LMW heparin effect on basal
thereby slowing the onset of albuminuria. Oral and par-promoter activity was abolished by mutation of the regulatory
enteral application of GAG decreased proteinuria inAP-1 box B and by deletion of this AP-1 binding site.
diabetic patients [21–24] and ameliorated glomeruloscle-Conclusions. LMW heparin prevents high glucose- and
PMA-mediated TGF-1 expression by inhibiting the activation rosis in diabetic rats [25]. Recent studies from our labora-
of the TGF-1 promoter and by preventing the enhanced bind- tory indicate that the renoprotective effect of the GAGs,
ing of nuclear proteins to the regulatory AP-1 site. particularly of LMW heparin, which was the most active
in these studies, can be explained as they prevent the
diabetes-induced renal up-regulation of TGF-1 [26].
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This inhibitory action takes place on a transcriptionalprotein kinase C, transcription factor AP-1, hyperglycemia, glomerulo-
sclerosis, mesangial matrix, renoprotection. level [26]. However, the molecular mechanism remains
unclear.Received for publication August 17, 2000
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Fig. 1. (A) The cis-regulatory elements in the
5-flanking region of the human transforming
growth factor- (TGF-1) gene. Positions are
deduced from sequence data as described by
Kim et al [29]. Symbols are: () activator pro-
tein-1 (AP-1)–like binding sites; () GC-
boxes. The AP-1–like sites A and B mediate
the high glucose and phorbol ester response
of the promoter and also are necessary for
basal promoter function [27]. Binding sites
used for electrophoretic mobility shift assays
(EMSAs) are indicated by asterisks. (B) Con-
structs of the 5-flanking region of the TGF-1
gene in pGL3basic, which contains the firefly
(photinus pyralis) luciferase coding region. The
pGL3/453 includes the wild-type TGF-1 frag-
ment 453/11 fused to the luciferase gene
and was used for the transfection experiments
shown in Figures 2–4. The pGL3/453Bmut con-
struct containing the mutated AP-1 binding
site as indicated was used for the transfection
experiments shown in Figure 5. The constructs
of the 5-flanking region of the TGF-1 gene
in pGL2/450 or pGL2/226 includes the wild-
type TGF-1 fragment 450/11 or the de-
leted TGF-1 promoter fragment 226/11
without both AP-1 sites.
of these sites has been identified as a functional AP-1 Boehringer (Mannheim, Germany). pSV--galactosidase
control vector, pRL-TK vector, and luciferase assay re-site (box B; Fig. 1A), because AP-1 proteins bound in
nuclear extracts of the unstimulated and stimulated cells, agent were from Promega (Madison, WI, USA). Protein
assay reagent was from Bio-Rad (Mu¨nchen, Germany).and mutation of box B resulted in the complete loss of
binding of nuclear proteins to this site. Furthermore, PMA was from Sigma (Mu¨nchen, Germany). [-32P]dATP
was from Hartmann (Braunschweig, Germany). Thethis mutation reduced the TGF-1 promoter activity to
approximately 60% of basal activity in high glucose- TGF-1-luciferase reporter vectors pGL3/453 and pGL3/
453Bmut (Fig. 1B) were prepared as described previouslystimulated, or PMA-stimulated, or in unstimulated mes-
angial cells [27]. [26]. pGL2/450 (450/11) and pGL2/226 (226/11;
Fig. 1B) were provided from A. Pfeiffer (Bochum, Ger-Therefore, our working hypothesis was that LMW
heparin exerts its beneficial effects by preventing the many). The LMW heparin (10.4 kD) was chemically
modified to yield a preparation with a sulfate/carboxylichyperglycemia-induced increase of TGF-1 promoter
activity. To address this question, an in vitro model was ratio of 1.35 showing very low anticoagulant activity (110
g/mL was necessary to induce a doubling of the aPTT)used to study the effects of LMW heparin on TGF-1
gene activation by a construct of the previously charac- [18]. The drug was from Alfa Wassermann SpA (Bolo-
gna, Italy).terized human TGF-1 promoter [28, 29]. Our results
indicate that LMW heparin prevents stimulation of
Cell cultureTGF-1 promoter activation by preventing the forma-
tion of an active transcription factor complex and/or Mesangial cells isolated from porcine glomeruli were
cultured and characterized as described previously [8].binding this complex to the regulatory AP-1 site of the
Cells were grown in RPMI 1640 with 15% FCS, 1 mmol/LTGF-1 promoter.
sodium pyruvate, 3 mmol/L glutamine, nonessential
amino acids, 100 U/mL penicillin, 100 g/mL streptomy-
METHODS
cin, 0.5 g/mL minocyclin, and 10 mmol/L glucose. For
Materials experimental purposes, RPMI 1640 containing 6 or 30
Oligonucleotides were synthesized by Life Technologies mmol/L glucose or 0.5 mol/L PMA solved in ethanol
(Karlsruhe, Germany). Cell culture media, supplements, was used. For equal osmolarity, NaCl was added. FCS
Ultroser, and fetal calf serum (FCS) were purchased from was substituted by 2% Ultroser.
GIBCO (Eggenstein, Germany); minocyclin was from Pan
Transfection methodsSystems (Aidenbach, Germany). Superfect was from Qia-
gen (Hilden, Germany). -Galactosidase assay chemilu- The mesangial cells were transfected with Superfect
from Qiagen according to the instructions of the supplier.minescent, Klenow enzyme, and poly[d(I-C)] were from
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One day prior to the transfection 2.0  105 cells/well Preparation of nuclear extracts
were seeded in six-well plates with 2 mL growth medium. For preparation of nuclear extracts, 5.6  106 cells
For each well, 2 g total DNA and 100 L RPMI 1640 were seeded onto 15 cm culture dishes and cultured in
without supplements were premixed; 10 L Superfect 15 mL medium for 24 hours. Cells were incubated with
was added, and the samples were mixed for 10 seconds. 0.5 mol/L PMA for six hours with or without 10 g/mL
After 10 minutes, the samples were diluted with 600 L LMW heparin before harvesting. Control cells received
growth medium, and the total volume was transferred ethanol. Nuclear proteins were prepared as described by
to the cells. After three hours, the transfection media Andrews and Faller [31], and the protein concentrations
were replaced by different culture media (6 or 30 mmol/L were determined according to Bradford using the Bio-
glucose) with or without LMW heparin, and cells were Rad protein assay reagent [32].
harvested after 24 hours. Preincubation was performed
Electrophoretic mobility shift assayby seeding and incubating the cells with 10 g/mL LMW
Appropriate oligonucleotides were end labeled withheparin 24 hours prior to transfection. For transfection
[-32P]dATP (3000 Ci/mmol/L) and Klenow enzyme.experiments with PMA, we used the Ca3(PO4)2-DNA
They were incubated with up to 13 g nuclear proteincoprecipitation method [30] because the Superfect inter-
in 20 L 7 mmol/L HEPES-KOH, pH 7.9, 100 mmol/Lfered with PMA. For each well, 4 g total DNA, 36 L
KCl, 3.6 mmol/L MgCl2, and 10% glycerol on ice forH2O, 160 L HBS 5/4 (50 mmol/L HEPES-KOH, pH
20 minutes; 0.05 mg/mL poly[d(I-C)] was added as an7.05, 172.5 mmol/L NaCl, 6.25 mmol/L KCl, 875 mol/L
unspecific competitor. The samples were run on a 5%Na2HPO4, 7 mmol/L glucose), and 10.4 L 2.5 mol/L
nondenaturating polyacrylamide gel in a buffer con-CaCl2 were mixed for 20 seconds, incubated for 20 min-
taining 25 mmol/L Tris-HCl, pH 8.0, 190 mmol/L glycine,utes, and added to the medium. After four hours, the
and 1 mmol/L ethylenediaminetetraacetic acid (EDTA).medium was replaced by 1 mL 10% glycerol in growth
Gels were dried and analyzed by autoradiography. Themedium, and cells were incubated for three minutes.
synthetic oligonucleotides used in electrophoretic mobil-Then, the glycerol medium was removed and the culture
ity shift assays (EMSA) correspond to base pairs 384/medium was added. After 20 hours, the cells were stimu-
352 (GGTCGGCTCCCCTGTGTCTCATCCCCCGlated with 0.5 mol/L PMA in the presence or absence
GATTAAC) and 229/198 (AGCCGGGGAGCCCof 10 g/mL LMW heparin and harvested after nine
GCCCCCTTTCCCCCAGGGCTG), and cover the AP-1hours. Control cells received ethanol. For normalization
B and Sp-1 binding sites as shown in Figure 1A.of transfection efficiencies, we cotransfected 0.25 g
pSV--galactosidase control vector. To study the effects Statistical analysis
of PMA, 0.5 g pRL-TK vector was used, which contains
The results presented were derived from at least three
the seapansy (renilla reniformis) luciferase gene under
independent experiments. Means  SEM were calcu-
the control of the herpes simplex virus thymidine kinase lated, and groups of data were compared using the Stu-
promoter, because the pSV--galactosidase vector re- dent t test. Statistical significance was set at P 	 0.05.
sponds to PMA. Both control vectors were only margin-
ally influenced by the LMW heparin treatment. Normal-
RESULTSization to the protein content yielded the same results.
Effect of LMW heparin on high glucose-induced
Reporter gene assays TGF-1 promoter activation
Transfected cells were washed once with phosphate- To study whether the high glucose-induced stimula-
buffered saline (PBS), incubated with 150 L lysis buffer tion of the TGF-1 promoter activity in the construct
from the -galactosidase chemiluminescent assay for 30 pGL3/453 (Fig. 1B) is affected by LMW heparin, trans-
minutes, and harvested. After two minutes of centrifuga- fected mesangial cells were cultured in 6 or 30 mmol/L
tion, the supernatants were stored at 80
C or were glucose for 24 hours in the presence or absence of LMW
immediately used for the measurements. -Galactosi- heparin. As shown in Figure 2A, glucose stimulated the
dase activities and firefly luciferase activities were deter- TGF-1 promoter activity up to 150%, while the addition
mined according to the manufacturer’s instructions. Co- of LMW heparin prevented this stimulation by decreas-
transfected firefly and seapansy luciferase activities were ing the promoter activity below the control value. LMW
assayed with the dual-luciferase reporter assay system heparin also slightly diminished the basal promoter activ-
from Promega. Chemiluminescence was determined ity. To exclude that the LMW heparin formulation di-
with a Magic Lite Analyzer from Ciba Corning (Essex, rectly influenced the assay system, cells were preincu-
UK). All transfection experiments were repeated at least bated with LMW heparin, and after transfection, cells
were cultured in high glucose medium without LMWthree times.
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Fig. 2. Effects of low-molecular-weight (LMW) heparin (Hep) on the Fig. 3. Effect of LMW heparin (Hep) on the phorbol myristate acetate
glucose-induced TGF-1 promoter activity. Mesangial cells were trans- (PMA)-stimulated promoter activity. Cells were transfected with pGL3/
fected with the wild-type plasmid pGL3/453 and cultured in 6 or 30 453, and nine hours before harvesting, 0.5 mol/L PMA dissolved in
mmol/L glucose with or without LMW heparin for 24 hours (A), or ethanol was added. Cells were incubated with LMW heparin during
cells were preincubated with LMW heparin for 24 hours prior to trans- the nine-hour PMA stimulation (A) or for 24 hours prior to transfection
fection, and afterwards grown in 6 or 30 mmol/L glucose (B). Luciferase (B). Promoter activity determined in transfected cells incubated with
activity is expressed as the percentage of the activity measured without ethanol as the control was set as 100%. Data are means  SEM of
LMW heparin and 6 mmol/L glucose. Data are from three independent three different experiments. *P 	 0.05, 0.5 mol/L PMA vs. control
experiments and are means SEM. *P	 0.05, 30 mmol/L vs. 6 mmol/L with ethanol; #P 	 0.05, 0.5 mol/L PMA with LMW heparin vs. 0.05
glucose; #P	 0.05, 30 mmol/L glucose with LMW heparin vs. 30 mmol/L
mol/L PMA without LMW heparin.
glucose without LMW heparin.
PMA-stimulated TGF-1 promoter induction (Fig. 3B).heparin. Preincubation with LMW heparin decreased
basal and high glucose-induced promoter activity to the In accordance with results shown in Figure 2, LMW
heparin reduced the basal promoter activity in both con-same extent (76 vs. 70%; Fig. 2B), with no difference in
the results obtained with a simultaneous addition of high ditions.
glucose and LMW heparin (Fig. 2B vs. Fig. 2A).
A dose-dependent reduction of high glucose-induced
TGF-1 promoter activity by LMW heparinEffect of LMW heparin on phorbol ester-induced
TGF-1 promoter activation To study the effect of increasing amounts of LMW
heparin on basal and high glucose–stimulated TGF-1To study whether the PMA-induced stimulation of the
TGF-1 promoter activity in the construct pGL3/453 was promoter activity, transfection experiments were per-
formed with mesangial cells cultured for 24 hours in 6 oraffected by LMW heparin, transfected mesangial cells
were cultured with 0.5 mol/L PMA for nine hours or 30 mmol/L glucose in the absence or presence of different
concentrations of LMW heparin. A dose-dependent andthe solvent ethanol (control) in the presence or absence
of LMW heparin. The twofold stimulation of the TGF-1 significant decrease of the high glucose-induced promoter
activity was found with 2.5 or moreg/mL LMW heparinpromoter region 453 to 11 induced by incubating
the cells with PMA was completely prevented by the (Fig. 4). Only 10 g/mL or more LMW heparin reduced
basal or stimulated promoter activity to approximatelysimultaneous addition of LMW heparin (Fig. 3A). Again,
preincubation with LMW heparin completely abolished 60%. For the remaining experiments, 10 g/mL were used
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Fig. 4. Dose-dependent effect of LMW heparin (Hep) on basal and
high glucose-stimulated TGF-1 promoter activity. Cells were trans- Fig. 5. Deletion of the AP-1 box B containing fragment 450/227
fected with pGL3/453 and were cultured for 24 hours in 6 or 30 mmol/L led to loss of the high glucose and the LMW heparin effect. Cells were
glucose in the absence or presence of increasing amounts of LMW transfected with pGL2/450 and pGL2/226 and stimulated with high
heparin. Promoter activity in 6 mmol/L glucose without LMW heparin glucose (HG) in the absence or presence of 10 g/mL LMW heparin.
was set as 100%. Data are means SEM of three different experiments. The activity of the promoter containing the wild-type TGF-1 promoter
*P 	 0.05, 30 mmol/L vs. 6 mmol/L glucose; §P 	 0.05, 6 mmol/L was set as 100%. Data are means SEM of three different experiments.
glucose with LMW heparin vs. 6 mmol/L glucose without LMW heparin; *P	 0.05, 30 mmol/L vs. 6 mmol/L glucose; #P	 0.05, 30 mmol/L glucose
#P	 0.05, 30 mmol/L glucose with LMW heparin vs. 30 mmol/L glucose with LMW heparin vs. 30 mmol/L glucose without LMW heparin.
without LMW heparin.
since this concentration was the same as that in our region containing the AP-1–like sites, and not by influ-
encing the Sp1 sites. Furthermore, these results supportprevious in vitro and in vivo studies [26].
our previous data showing that the AP-1–like binding
Effects of LMW heparin on the TGF-1 promoter sites contribute to the basal promoter function [27].
region 226/11 and on the high glucose and PMA To study the participation of the AP-1 box B in LMW
response of the promoter mutated at the AP-1–like heparin action further, we used the wild-type and the
binding site 371/364 box B-mutated TGF-1 promoter constructs [27]. As
shown previously, a mutation in box B of the TGF-1As shown previously, two AP-1–like binding sites, lo-
cated in the TGF-1 promoter region 453 to 323, promoter prevented the high glucose-induced gene acti-
vation of TGF-1 (Fig. 6A) [27]. The stimulated andmediated high glucose and phorbol ester stimulation,
since mutation of either one of the two elements abol- basal values were reduced to approximately 50% of the
control value. Furthermore, incubation of the transfectedished the promoter activation completely (Fig. 1A) [27].
One of these promoter elements, box B, was character- cells with LMW heparin essentially had no additional
effect on the promoter activity of stimulated or unstimu-ized as a functional AP-1 binding site [27], and only this
AP-1 box B mediated promoter activation by expression lated cells. Similar effects were obtained with PMA-
stimulated cells (Fig. 6B). Taken together, these resultsof a c-Jun/c-Fos complex in transfection experiments (C.
Weigert, unpublished results). To study the role of both suggest that the inhibitory action of LMW heparin is
mediated through the regulatory AP-1 binding site.AP-1–like binding sites in the LMW heparin-mediated
inhibition of basal TGF-1 promoter activity, mesangial
LMW heparin prevents the binding of nuclearcells were transfected with the deleted TGF-1 pro-
proteins to the AP-1 site 371/364 of the TGF-1moter-luciferase construct, which contained only the re-
promoter in basal and stimulated mesangial cellsgion226/11 with several Sp1 sites (Fig. 1B). Deletion
of the promoter region 450 to 227, containing the To investigate further the molecular mechanism of the
inhibitory action of LMW heparin, the binding of nuclearAP-1–like binding sites, caused a reduction of the basal
promoter activity to 55  5% and abolished the high proteins to the regulatory AP-1 box B (371/364) in
unstimulated, high glucose-, and PMA-activated nuclearglucose-induced increase in TGF-1 promoter activity
(Fig. 5). No additional inhibitory effect was observed in extracts of mesangial cells was studied in EMSAs. Stimu-
lation of mesangial cells with high glucose for 24 hoursthe presence of 10 g/mL LMW heparin. The addition
of LMW heparin decreased the promoter activity of the induced an increase in the binding of nuclear proteins
to the AP-1 site (Fig. 7A, lane 3 vs. lane 1). Simultaneousundeleted promoter region450/11 in ambient normal
and high glucose concentrations similar to the values incubation of the cells with LMW heparin decreased
basal and stimulated DNA binding (Fig. 7A, lanes 2 andobtained with the deleted construct. These results indicate
that LMW heparin exerts its inhibitory action on TGF-1 4). Specific binding to the AP-1 site was confirmed by
the addition of 10- and 30-fold molar excess of coldpromoter activity through the 450 to 227 promoter
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DNA binding activity by high glucose (Fig. 7D) and
sevenfold stimulation by the addition of PMA (Fig. 7E),
and a reduction by LMW heparin to 1.2-fold (Fig. 7D)
and 1.7-fold (Fig. 7E) compared with the control value.
DISCUSSION
The present study investigated whether LMW heparin
regulates TGF-1 gene expression by suppressing the
high glucose- and phorbol ester-induced TGF-1 pro-
moter activity. The experiments were performed with
LMW heparin, an effective GAG formulation that has
been used in our previous in vivo and in vitro studies.
Four lines of evidence show that LMW heparin prevents
the increase in TGF-1 gene activation in high glucose-
and phorbol ester-stimulated mesangial cells. First, the
high glucose- and PMA-induced TGF-1 promoter acti-
vation was completely prevented by a simultaneous addi-
tion LMW heparin. Second, the LMW heparin-induced
reduction of promoter activity was dose dependent.
Third, the inhibitory effect was maintained in mesangial
cells preincubated with LMW heparin for 24 hours. Fi-
nally, LMW heparin completely suppressed both the
high glucose and the PMA-enhanced binding of nuclear
proteins to the regulatory AP-1 binding site, which medi-
ates the high glucose and PMA responsiveness of the
TGF-1 promoter [27]. LMW heparin had no effect on
nuclear protein binding to the Sp1 site, indicating the
specificity of the observed effect. The results clearly show
Fig. 6. Effect of high glucose (A), PMA (B), and LMW heparin on
that the inhibitory action of LMW heparin takes place onthe TGF-1 promoter activity containing a mutated AP-1 site box B
(Bmut). Cells were transfected with pGL3/453Bmut, which contains a the level of TGF-1 gene activation, thereby preventing
TGF-1 promoter fragment with a mutation in the AP-1 box B site. increased de novo synthesis of TGF-1. However, our
Cells were stimulated with high glucose (HG; A) or PMA (B) in the
studies do not exclude that LMW heparin has an addi-presence or absence of 10 g/mL LMW heparin. The activity of the
promoter containing the wild-type TGF-1 promoter was set as 100%. tional effect on post-translational mechanisms that may
Data are means  SEM of three different experiments. modify the level of functionally active TGF-1.
The finding that LMW heparin inhibits hyperglycemia-
induced TGF-1 gene activation in mesangial cells is
well in line with our previous report, demonstrating theoligonucleotide (Fig. 7A, lanes 5 and 6). Stimulation of
prevention of high glucose-stimulated TGF-1 mRNAmesangial cells with 0.5 mol/L PMA for six hours in-
and protein expression by LMW heparin (10 g/mL)duced a strong increase in nuclear protein binding to the
[26]. Furthermore, the dose dependency found for theAP-1 site (Fig. 7B, lane 3 vs. lane 1). The addition of
inhibition of stimulated TGF-1 promoter activity in ourLMW heparin reduced the weak but significant binding
current study is similar to the dose dependency foundin control extracts (Fig. 7B, lane 2) and completely pre-
for the inhibition of the TGF-1 mRNA levels [26]. Thevented the PMA-induced enhanced DNA binding activ-
present study also shows that the regulatory AP-1 siteity (Fig. 7B, lane 4). To exclude unspecific interactions
B (371/364), which mediates the high glucose andof LMW heparin with nuclear proteins, the effect of
PMA response of the TGF-1 promoter, is involved inLMW heparin on the binding to the Sp1 site 220/211
the inhibitory action of LMW heparin because (1) dele-was studied. PMA stimulation influenced the binding
tion of the promoter region 450/227, which containsonly marginally, while no inhibitory effect of LMW hepa-
this AP-1 site, resulted in the loss of an inhibitory actionrin on the binding of nuclear proteins to the Sp1 site
of LMW heparin; (2) mutation of the regulatory AP-1was observed in control or PMA-stimulated cells, indi-
site or presence of LMW heparin caused the same pre-cating that LMW heparin does not interfere specifically
ventive effect, but together they were not additive; andwith DNA binding (Fig. 7C). Densitometric quantifica-
(3) the addition of LMW heparin to mesangial cells pre-tion of the binding of the AP-1–like proteins in three
independent experiments shows twofold stimulation of vented the high glucose- and phorbol ester-stimulated en-
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Fig. 7. Effect of LMW heparin on the binding of nuclear proteins of
control, high glucose-, and PMA-activated mesangial cells to the AP-1
binding site B of the TGF-1 promoter. Mobility shift experiments
were performed with nuclear extracts from mesangial cells cultured for
24 hours and were activated with 30 mmol/L glucose for 24 hours or
0.5 mol/L PMA six hours before harvesting. Thirteen micrograms of
nuclear proteins were incubated with 50,000 cpm of the 32P-labeled
oligonucleotides, which include the AP-1 box 371/364 or the Sp1
site 220/211 of the TGF-1 promoter. (A) Binding of nuclear pro-
teins from normal glucose and high glucose-treated cells to the AP-1
site B. LMW heparin was added 24 hours before harvesting, as indicated
in the lanes 2 and 4. Specific binding of AP-1–like proteins was confirmed
by 10- and 30-fold molar excess of cold AP-1 box B oligonucleotides,
as indicated by the bracket. (B) Binding of nuclear proteins from control
and PMA-stimulated cells to the AP-1 site B. LMW heparin was added
six hours before harvesting, as indicated in lanes 2 and 4. Specific binding
of AP-1 like proteins is indicated by a bracket. (C) Binding of nuclear
proteins from control and PMA-stimulated cells to the Sp1 binding site
with or without incubation with LMW heparin for six hours. Specific
binding of Sp1-like proteins is indicated by a bracket. (D) Scanning
densitometry of three independent mobility shift experiments with the
AP-1 box B and nuclear extracts of high glucose-stimulated cells. The
intensity of the specific shifted bands of unstimulated cells in the absence
of LMW heparin was set as 1.0. Data are means  SEM. (E ) Corre-
sponding scanning densitometry of three independent mobility shift
experiments with the AP-1 box B and nuclear extracts of PMA-stimu-
lated cells.
hanced binding of nuclear proteins to the AP-1 box B. regulatory AP-1 site was accompanied by a reduction in
the binding of nuclear proteins to the mutated AP-1 site,The fact that the addition of 10 and 40 g/mL LMW
heparin decreased the basal TGF-1 promoter activity indicating the involvement of this promoter element in
the basal promoter function [27]. Together, the resultscan be explained by our finding that a weak binding of
nuclear proteins to this AP-1 site in unstimulated cells that were obtained by very different experimental proce-
dures indicate that the inhibitory effect of LMW heparinwas observed, and this was prevented by the addition of
LMW heparin. Furthermore, as reported previously [27], on TGF-1 promoter induction was abolished by the
LMW heparin-mediated prevention of the stimulatedmutation of the regulatory AP-1 site led to a reduction
of the basal TGF-1 promoter activity of approximately binding of nuclear proteins to the regulatory AP-1 site.
The present data indicate that LMW heparin acts by60% of the control value, and this was similar to the
value found in the present experiments. This reduction inhibiting the formation of an active transcription factor
complex and/or the binding to the regulatory AP-1 siteof TGF-1 promoter activity induced by mutation of the
Weigert et al: LMW heparin and TGF-b1 gene activation942
box B, which is responsible for the TGF-1 gene activa- gene activation, and support the renoprotective effects
of GAGs in diabetic patients by the proposed moleculartion. We have previously demonstrated that high glu-
cose- or PMA-induced stimulation of mesangial cells leads mechanism.
to TGF-1 promoter activation, and that this activation
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results indicate that, at least in part, the inhibitory action
of LMW heparin is mediated by inhibition of the PKC
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